Combination of biomarkers for detecting and evaluating a hepatic fibrosis
The application concerns means for determining the stage of hepatic tissue damage, in particular the hepatic fibrosis score of subjects infected with one or more hepatitis viruses. In particular, the means of the invention involve measuring the levels of expression of selected genes, said selected genes being: SPP1, and at least one gene from among A2M and VIM, and at least one gene from among IL8, CXCL10 and ENG, and optionally, at least one gene from among the list of the following sixteen genes: IL6ST, p14ARF, MMP9, ANGPT2, CXCL11, MMP2, MMP7, S100A4, TIMP1, CHI3L1, COL1A1, CXCL1, CXCL6, IHH, IRF9 and MMP1.
1. A kit comprising reagents attached to a solid support that specifically detect A2M, MMP7, and TIMP1, wherein said reagents are nucleic acids that hybridize specifically to RNA transcribed from A2M, MMP7, and TIMP1 and/or to the cDNA obtained by reverse transcription of said RNAs, or are proteins, polypeptides or peptides that specifically bind to the proteins encoded by A2M, MMP7, and TIMP1.
2. The kit of claim 1 , wherein said reagents attached to said solid support further comprise amplification primers and/or nucleic acid probes that hybridize specifically to RNA transcribed from SPP1, VIM, IL8, CXCL10, ENG, IL6ST, p14ARF, MMP9, ANGPT2, CXCL11, MMP2, S100A4, CHI3L1, COL1A1, CXCL1, CXCL6, IHH, IRF9 and MMP1 and/or to the cDNA obtained by reverse transcription of said RNAs, or are antibodies or fragments of antibodies or protein, polypeptide or peptide aptamers that specifically bind to the proteins encoded by SPP1, VIM, IL8, CXCL10, ENG, IL6ST, p14ARF, MMP9, ANGPT2, CXCL11, MMP2, S100A4, CHI3L1, COL1A1, CXCL1, CXCL6, IHH, IRF9 and MMP1.
3. The kit of claim 2 , wherein said reagents attached to said solid support further comprise nucleic acid probes that hybridize specifically to RNA transcribed from SPP1, VIM, IL8, CXCL10, ENG, IL6ST, p14ARF, MMP9, ANGPT2, CXCL11, MMP2, S100A4, CHI3L1, COL1A1, CXCL1, CXCL6, IHH, IRF9 and MMP1 and/or to the cDNA obtained by reverse transcription of said RNAs.
4. The kit of claim 2 , wherein said reagents attached to said solid support further comprise amplification primers that hybridize specifically to RNA transcribed from SPP1, VIM, IL8, CXCL10, ENG, IL6ST, p14ARF, MMP9, ANGPT2, CXCL11, MMP2, S100A4, CHI3L1, COL1A1, CXCL1, CXCL6, IHH, IRF9 and MMP1 and/or to the cDNA obtained by reverse transcription of said RNAs.
5. The kit of claim 2 , wherein said reagents attached to said solid support further comprise amplification primers and nucleic acid probes that hybridize specifically to RNA transcribed from SPP1, VIM, IL8, CXCL10, ENG, IL6ST, p14ARF, MMP9, ANGPT2, CXCL11, MMP2, S100A4, CHI3L1, COL1A1, CXCL1, CXCL6, IHH, IRF9 and MMP1 and/or to the cDNA obtained by reverse transcription of said RNAs.
6. The kit of claim 2 , wherein said reagents attached to said solid support further comprise fragments of antibodies or protein, polypeptide or peptide aptamers that specifically bind to proteins encoded by SPP1, VIM, IL8, CXCL10, ENG, IL6ST, p14ARF, MMP9, ANGPT2, CXCL11, MMP2, S100A4, CHI3L1, COL1A1, CXCL1, CXCL6, IHH, IRF9 and MMP1.
7. The kit of claim 6 , wherein said reagents said reagents attached to said solid support further comprise further comprise antibodies or fragments of antibodies that specifically bind to proteins encoded by SPP1, VIM, IL8, CXCL10, ENG, IL6ST, p14ARF, MMP9, ANGPT2, CXCL11, MMP2, S100A4, CHI3L1, COL1A1, CXCL1, CXCL6, IHH, IRF9 and MMP1.
8. The kit of claim 6 , wherein said reagents attached to said solid support further comprise protein, polypeptide or peptide aptamers that specifically bind to proteins encoded by SPP1, VIM, IL8, CXCL10, ENG, IL6ST, p14ARF, MMP9, ANGPT2, CXCL11, MMP2, S100A4, CHI3L1, COL1A1, CXCL1, CXCL6, IHH, IRF9 and MMP1.